Adlai NortyeANL -1.57% Current Ratio is 0.65 as of Dec. 2025, which is 54% below its 10-year median of 1.41. The stock has 7 warning signs investors should review. Among 1,413 Biotechnology companies, Adlai Nortye ranks worse than 89.38% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Adlai Nortye's current ratio for the quarter that ended in Dec. 2025 was 0.65.
Adlai Nortye has a current ratio of 0.65. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Adlai Nortye has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Adlai Nortye's Current Ratio or its related term are showing as below:
ANL'
s Current Ratio Range Over the Past 10 Years
Min: 0.21 Med: 1.41 Max: 7.12
Current: 0.65
During the past 5 years, Adlai Nortye's highest Current Ratio was 7.12. The lowest was 0.21. And the median was 1.41.
ANL's Current Ratio is ranked worse than 89.38% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs ANL: 0.65
Adlai Nortye (NAS:ANL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Adlai Nortye Current Ratio Related Terms
Adlai Nortye Current Ratio Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Current Ratio distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a Current Ratio of 0.65 as of Dec. 2025. This is 54% below median its historical median of 1.41. Over the past decade, Adlai Nortye's Current Ratio has ranged from 0.21 to 7.12. According to the industry distribution chart, Adlai Nortye ranks #1263 out of 1413 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Adlai Nortye's Current Ratio too high?
Adlai Nortye's current Current Ratio of 0.65 is 54% below median its 10-year median of 1.41. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 7.12. The Biotechnology industry median Current Ratio is 3.89. Adlai Nortye's value of 0.65 is 83.3% below this industry median. Based on the distribution chart, Adlai Nortye ranks #1263 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Current Ratio compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #1263 out of 1413 companies for Current Ratio. This places Adlai Nortye in the lower half of its industry. The industry median Current Ratio is 3.89. Adlai Nortye's value of 0.65 is 83.3% below this benchmark. Historically, Adlai Nortye's own Current Ratio has ranged from 0.21 to 7.12 over the past decade. While the company's 10-year median is 1.41 vs. the industry median of 3.89, Adlai Nortye has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current Current Ratio of 0.65 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Current Ratio is 0.65, which is 54% below median its own 10-year median of 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Current Ratio of 0.65. The current Current Ratio is 0.65, which is 54% below median its 10-year median of 1.41 and 83.3% below the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Current Ratio is 0.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 